These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18058075)

  • 21. Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation.
    Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Park JS
    J Korean Med Sci; 2015 Oct; 30(10):1416-22. PubMed ID: 26425037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
    Wei AH; Döhner H; Pocock C; Montesinos P; Afanasyev B; Dombret H; Ravandi F; Sayar H; Jang JH; Porkka K; Selleslag D; Sandhu I; Turgut M; Giai V; Ofran Y; Kizil Çakar M; Botelho de Sousa A; Rybka J; Frairia C; Borin L; Beltrami G; Čermák J; Ossenkoppele GJ; La Torre I; Skikne B; Kumar K; Dong Q; Beach CL; Roboz GJ;
    N Engl J Med; 2020 Dec; 383(26):2526-2537. PubMed ID: 33369355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Should patients over 65 years old with acute myeloid leukemia be treated with myelosuppressive chemotherapy?].
    Spataro V; Cometta A; Glauser MP; Schapira M; Grob JP
    Schweiz Med Wochenschr; 1995 Mar; 125(9):429-32. PubMed ID: 7892571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
    Bradstock KF; Link E; Di Iulio J; Szer J; Marlton P; Wei AH; Enno A; Schwarer A; Lewis ID; D'Rozario J; Coyle L; Cull G; Campbell P; Leahy MF; Hahn U; Cannell P; Tiley C; Lowenthal RM; Moore J; Cartwright K; Cunningham I; Taper J; Grigg A; Roberts AW; Benson W; Hertzberg M; Deveridge S; Rowlings P; Mills AK; Gill D; Bardy P; Campbell L; Seymour JF;
    J Clin Oncol; 2017 May; 35(15):1678-1685. PubMed ID: 28368672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
    Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P
    Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.
    Jehn U
    Leuk Lymphoma; 1994 Sep; 15(1-2):99-112. PubMed ID: 7532060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults.
    Phillips GL; Reece DE; Shepherd JD; Barnett MJ; Brown RA; Frei-Lahr DA; Klingemann HG; Bolwell BJ; Spinelli JJ; Herzig RH
    Blood; 1991 Apr; 77(7):1429-35. PubMed ID: 2009367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute myeloid and lymphoblastic leukemia in adults. The course of the disease in 315 patients from one region, during a ten-year period.
    Johnsen HE; Bergmann OJ; Ellegaard J; Bastrup-Madsen P
    Dan Med Bull; 1989 Apr; 36(2):189-93. PubMed ID: 2707057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
    Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-remission therapy in acute myeloblastic leukemia. A randomized trial comparing early consolidation plus maintenance versus maintenance therapy alone.
    Maldonado J; Gardella S; Rodriguez Fernandez JM; Parody R; Muncunill J; Vivancos P; Alonso C; Hernandez-Nieto L; Domingo A; Marin J
    Acta Oncol; 1989; 28(2):223-6. PubMed ID: 2660862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [High dosage ARA-C in combination with mitoxantrone in therapy of acute myeloid leukemia in childhood. Initial results of the AML BFM-85 recurrence study].
    Ritter J; Creutzig U; Henze G; Jürgens H; Bode U; Prindull G; Schellong G
    Onkologie; 1987 Feb; 10(1):24-7. PubMed ID: 3295622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).
    Blum W; Sanford BL; Klisovic R; DeAngelo DJ; Uy G; Powell BL; Stock W; Baer MR; Kolitz JE; Wang ES; Hoke E; Mrózek K; Kohlschmidt J; Bloomfield CD; Geyer S; Marcucci G; Stone RM; Larson RA;
    Leukemia; 2017 Jan; 31(1):34-39. PubMed ID: 27624549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maintenance therapy in childhood acute myeloid leukemia.
    Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
    Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensive maintenance treatment in acute myelogenous leukemia (AML): single institution experience of a multicenter randomized trial.
    Jehn U; Knüppel W; Wilmanns W
    Onkologie; 1988 Feb; 11(1):13-7. PubMed ID: 3283620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Revisiting maintenance therapy in acute myeloid leukemia with novel agents.
    Canaani J; Luger SM
    Curr Opin Hematol; 2016 Mar; 23(2):175-80. PubMed ID: 26766539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
    Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG
    Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel postremission strategies in adults with acute myeloid leukemia.
    Lancet JE; Karp JE
    Curr Opin Hematol; 2009 Mar; 16(2):105-11. PubMed ID: 19468272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
    Ferrero D; Crisà E; Marmont F; Audisio E; Frairia C; Giai V; Gatti T; Festuccia M; Bruno B; Riera L; Passera R; Boccadoro M
    Ann Hematol; 2014 Aug; 93(8):1391-400. PubMed ID: 24705888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [AML-6 and AML-7 studies on the treatment of acute myelocytic leukemia. Cyclic alternating chemotherapy during remission, and induction of remission and survival of elderly patients].
    Jehn U; Zittoun R; Löwenberg B
    Onkologie; 1985 Jun; 8(3):160-4. PubMed ID: 3895099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.